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B 4.2 Pharmacotherapy for Symptoms of Intermittent Claudication
B 4.2.1 Introduction
Patients with intermittent claudication mostly receive drug treatment for coexisting disease (eg,
hypertension), risk factor modification (eg, hyperlipidemia), and as prophylaxis against throm-
botic events associated with atherosclerosis (eg, antiplatclet drugs). No pharmacological agent
has proved efficacious enough in providing significant reduction or elimination of symptoms of
claudication to gain widespread acceptance and use for improving walking. However, a number
of types of drugs have been promoted for this indication, with varying evidential support, and
these will be considered in this section. These drugs are frequently grouped together under the
heading "vasoactive agents," partly because of their multiplicity of potential mechanisms of
action. Some of the drugs have been distinguished as "rheologic agents," but tor others such
as prostanoids, the mode of action is still not well delineated. These drugs should not replace
exercise programs and other lifestyle adjustments described in B 4.1.2, Basic Treatment (p
S80). However, they have a place as adjunctive treatment where invasive therapy is not indicat-
ed, in those who cannot or will not follow exercise therapy or in those who have not sufficient-
ly benefited from it (see D 4.13.5, Adjuvant Therapy, p 5250). Table 16 and Figure 20 show
results of randomized, placebo-controlled, double-blind trials of pharmacotherapy in Ie.
B 4.2.2 Established Drugs With Proven but Small Benefit in Improving Claudication
Pentoxifylline
Pentoxifylline improves red cell deforrnability, lowers fibrinogen levels, decreases platelet aggre-
gation, and has been shown to increase walking distance in patients with PAD. In early con-
trolled trials, the drug produced a 22% improvement over placebo in leD and a 12%improve-
ment in the ACD.l However, these percent improvements wen; expressed as the mean differ-
ence between week 2 and week 24. The actual improvement over placebo from entry to 6
months in ACD was 18%, but this difference was not statistically significant. A more recent
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Table 16. Randomized, placebo-controlled, double-blind trials ofphannacotherapy in intermittent claudication
Duration fj.ACD (%)
N Dose (weeks) Placebo Dml! p valu« WIQlSF-36 , Comments
Cilostazol:
Money et al, 1998 12 239 200 mg/d 16 13 47 <0.001 Yes
Dawson et al, 1998 13 81 200 mg/d 12 10 63 <0.01 Yes
Pentoxifylline:
Lindgarde et al, 19892 150 1.2 gld 24 29 50 0.09 No
(subset) 109 1.2 g/d 24 30 63 <0.05 No
Porter et al, 19821 128 J.2 g/d 24 38 56 0.19 No
Naftidrofilry/:
Moody et al,7 1984 180 633 mg 24 t25 t 31 0.045 Yes lCD data
only
Kriessmann & Neiss.s 1988 136 633 mg 12 35 78 <0.05 No lCD data
only
Adhoure er ai,S 1990 118 600 mg 24 46 93 <0.05 No lCD data
only
Trubestein et al,8 1994 104 600 mg 12 40 55 NS No
Adhoute et aI,4 1986 94 633 mg 24 28 60 <0.001 Yes
Btif1omedil:
Trubestein 19849 113 600 mg 14 43 97 <0.01 No
Diarnantopoulos et al,IO 1989 34 600 mg 24 9 68 0.011 No All diabetic
patients
Ticlopidine:
Balsano et alp 1989 151 500l11g/d 21 rno 38 71 <0.01 No
Verapami/:
Bagger et aI,23 1997 44 120-480 mg 2 -2 49 <0.001 No Cross-
over trial
Dextran:
Ernst et al,24 1990 20 500 mL 6 0 39 <0.001 No Cross-over
trial
Hexopa/:
Kiff,31 1988 80 4g/d 12 87 50 NS Yes
Cinnarizine:
Barber et aI,29 1980 45 225 mg 16 11 142 No rCD data
only
Donald,30 1979 40 225 mg 12 34 113 NS No lCD data
only; cross-
over trial
Staessen,28 1977 26 200 mg 16 30:j: 75:j: <0.05 Yes Phenob-
arbitone-
placebo
Propionyi-Lrcarnitine:
Brevetti er al,32 1995 245 1-3 g/d 24 46 73 <0.05 No
Brevetri et al,33 1996 485 2 g/d 52 50 64 <0.05 No
Beraprost:
Lievre et aI,34 1996 83 120 g/d 12 41 91 NS No Optimal
dose group
PGE1:
Diehm et al,35 1997 213 60 rngyd 8 60 101 <0.05 No
Belch ct al,36 1997 80 3 doses 8 -14 53 <0.01 Yes
NOTE. fj.ACD=%change in absolute walking distance; NS, not significant.
'Functional assessment as defined by WlQ and SF-36.
t Percentage of patients with ;::50% increase in baseline ACD.
:j:Percentagc of patients with 100% or greater increase in baseline ACD.
study confirmed these results, with a 21% improvement over placebo (p = 0.09).2 The study
showed that a Sll bgroup of patients with symptoms for longer than a year and an ABPI < 0.80
responded better to the drug. Importantly, patient-based questionnaires to assess efficacy have
not been employed in the clinical trials of pentoxifylline, so the actual clinical benefit of the
drug has not been fully defined.
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Figure 20: Randomized placebo-controlled, double-bli nd trials of pharmacotherapy in intermi ttent claudication.
• Thickness of bars Indicates total number of patients In trial
From Table 16. Studies with fewer than 50 patients are omitted.
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Naftidrofuryl
Naftidrofiiryl has been available for treating Iefor over 20 years. It is a 5H T antagonist and may
improve aerobic metabolism in oxygen-de pleted tissues and possibly reduce erythrocyte and
platelet aggregation.f In four placebo-controlled studies, Naftidrofuryl was more effective than
placebo in improvi ng walking distance,4,S,6,7 and a fur ther study showed no significant difference.f
Buflomedil
Buflomedil has an alpha-I and -2 adrenolytic effect. It has been shown to decrease vasoconstric-
tion . It has also been shown to have some effect on platelets, red cell deforrnability, and a weak
calcium antagon ist effect. Buflorncdil has been available for the treatment of Ie in some coun-
tries for over 10 years. Two relatively small studies, conducted more than 10 years ago, showed
a significantly greate r improvement in absolute walking distance with Buflomedil compared with
placcbo .9, l O
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Cilostaeol
Cilostazol is a phosphodiesterase III inhibitor with vasodilator and antiplatelet activity.U The
first published double-blind trial showed a 47% increase in ACD in the treatment group com-
pared to 13% increase in the placebo group (Table 16),12 This trial also showed that all sub-
groups of patients (age, smoking status, gender, race, and diabetes) responded equally well to
cilostazol, Quality of life was assessed in this trial using the medical outcomes study SF-36 ques-
tionnaire. This showed that patients on cilostazol had significant improvement in their physical
functioning relative to those on placebo. They reported improved physical performance in the
community setting. Mental health scores were unaffected by treatment. Side effects included
headache, diarrhea, and dizziness. Further randomized multicenter studies have been pub-
lished 13,14 and also show consistent improvements in rCD and ACD in the cilostazol group as
compared with placebo. Subjective functional assessment was not well assessed but did suggest
that there was drug effect, as noted by both patients and physicians.If
B 4.2.3 Drugs With Minimal or No Benefit in Improving Claudication
Antiplatelet drugs
As discussed previously, the use of aspirin and other antiplatelet agents are important in the
long-term treatment of peripheral atherosclerosis assuming a significant degree of multisystem
involvement, mainly to reduce the overall incidence of cardiovascular events (see
Recommendation 28, p S83). However, no studies have shown a benefit of aspirin in the treat-
ment of claudication per se, although there is one study that presented suggestive evidence that
aspirin slowed progression of atherosclerosis assessed by serial angiography.Js In contrast, ticlo-
pidine, a potent inhibitor of platelet aggregation that also has hemorheologic effects, was shown
in two randomized, placebo-controlled trials to improve claudication symptoms and exercise
performance17,18 (Table 16). However, only one of these studies, by Balsano et al, had evaluable
data. In that trial, treadmill testing was performed on the flat, and therefore, the clinical benefits
of the drug may have been overestimated because of the very low treadmill workload.
Vasodilators
Arteriolar vasodilators were the first class of agents used to treat claudication. Examples include
drugs that inhibit the sympathetic nervous system (alpha blockers), direct-acting vasodilators
(papaverine), betaj agonists (nylidrin), calcium channel blockers (nifedipine), and angiotensin-
converting enzyme inhibitors. These drugs have not been shown to have clinical efficacy in ran-
domized, controlled trials,19,20,21 There are several theoretical reasons why vasodilators may not
be effective. Most importantly, in the exercising claudicanr, vessels in ischemic areas are already
maximally dilated, so vasodilator drugs will only create a steal phenomena by dilating vessels in
normally perfused tissues (primarily proximal muscles), thus shifting the distribution of blood
flow away from muscles supplied by obstructed arteries.
Ketanserin
Ketanserin is a selective serotonin (52) antagonist that lowers blood viscosity and also has
vasodilator and antiplatelet properties. Controlled trials of this drug have shown it not to be
effective in treating claudication.R
Verapamil
One study has looked at the possibility that the calcium antagonist verapamil may have a clinical
benefit in patients with intermittent claudication. Although treatment was only for 2 weeks and
the study design could be criticized, the ACD was statistically significantly greater in the treated
than in the placebo group.23
Isovolemic hemodilution
Isovolemic hemodilution has been advocated for the treatment of IC even in the absence of
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polycythemia. No doubt, hemodilution lowers the viscosity of whole blood, but it is still uncer-
tain whether the in crease in blood flow compensates for the decrease in oxygen-carrying capaci-
ty of the blood. One double-blind, placebo controlled trial of dextran hemodilution showed
efficacy in selected patients.24
Aminophylline
Aminophylline inhibits adenosine receptors and thus may blunt the vasodilatation response dur-
ing exercise . This effect would theoretically limit the steal of blood away from ischemic skeletal
muscle. One study has shown that intravenous aminophylline improves t readmill exercise perfor-
mance in patients with claudication.tf
VitaminB
Five randomized controlled trials have been published since 1953 regarding the use of vitamin
E and the treatment of claudication. Although some results arc encouraging, there is insufficient
evidence to recommend the routine use of vitamin E in patients with IC.26
Defibrotide
Defibrotide is a polydeoxyribonucleotide drug with antith rombotic and hemorheological prop-
erties. A meta-analysis was performed in 1994 on 10 placebo-controlled trials of dcfibrotide in
patients with PAD stage II (406 patients on defibrotide, 337 patients on placebo ). The drug
was used at a dose of 400 to 800 mg daily, the treatment ranging from 60 to 180 days. There
was a net gain in absolute walking distance over placebo of 73 rn (95%confidence interval;
range, 35-111 111 ) .27
Other vasoactive drugs
Other drugs that have been promoted include cinnarizine,18,29,30 cyclandel ate, nicotinic acid
derivatives , 31 ginkgo biloba, and Isosuprine . However, there is no consistent scientific evidence
of efficacy for any of these.
Recommendation 30: Pharmacotherapy for symptoms of intermittent claudication
Although some controlled clinical trials with pentoxifylline, naftidrofuryl, buflomedil,
and recently cilostozol, have shown statistically significant improvement in walking dis-
tance, the average benefit was small. Greater benefit, observed in a minority of patients,
may warrant a short course of therapy with continued use of such agents if sufficient
benefit is observed. Recent clinical trials have shown a greater benefit of cilostazol for
both walking distance and quality of life, which may warrant more widespread use.
However, currently there are insufficient data to recommend the routine use of pharma-
cotherapy in all patients with claudication.
B 4.2.4 Incompletely Studied Drugs With Potential Benefit in Improving Claudication
Carnitine
Patients with PAD not only have a limited arterial blood flow but also develop metabolic abnor-
malities in their skeletal muscle. An example of this is changes in carnitine metabolism. Patients
with PAD have been shown to accumulate acylcarnitines (intermediates of oxidative metabo-
lism) in their skeletal muscle.f? This abnormal accumulation of acylcarnitines is directly correlat-
ed with impaired exercise performance. It has thus been hypothesized that supplementation of
patients with carnitine would improve ischemic muscle metabolism. Carnitine, and an acyl form
of carnitine (propio nyl-i-carnitine), are drugs that have been shown to increase exercise perfor-
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mance and improve claudication symptoms in small phase II trials.38,39 Larger phase II trials
have also shown benefit of propionyl-L-carnitine, with the optimal dose of 2 g/d,32,33 (Table
16). Three multicenter, phase III trials are evaluating the efficacy and safety of propionyl-Lscar-
nitine in the treatment of claudication.ef
Prostaglandins
Prostaglandins have been used in several studies in patients with CLI, with some success. In one
open-label study of claudicants, 44 patients were treated either without an infusion (control
group), with intravenous pentoxifylline, or with intravenous prostaglandin E1 (PGE1) for 4
weeks.s! All patients also underwent an exercise rehabilitation program. The exercise program
alone resulted in a 99% increase in maximal walking distance; pentoxifylline, a 119% increase;
and PGE1 a 371%increase. Because this trial was unblinded and not placebo controlled, and
patients h~d a combined intervention of exercise training and drug, the results need to be con-
firmed with additional studies.
A prodrug of PGE 1 (AS-Ol3) was studied in a randomized, controlled, prospective study of 80
patients with Ie, comparing placebo with three dosage regimens of the drug given intravenous-
ly for 5 days per week over 8 weeks. There was a significantly greater increase (p < 0.01) in
maximum walking distance in the combined active treatment group (53%) compared with the
placebo group (-14%). There was also a dose-related improvement in the response to a quality-
of-life questionnaire. 36 In another recent study, intravenous PGE 1 given for 5 days per week
over 4 weeks and twice weekly per week for a further 4 weeks was compared with placebo in
213 claudicants. At the end of the 8 weeks of treatment, pain-free walking distance increased by
60% in the placebo group compared wid1101% in the treated group (p < 0.05). These improve-
ments remained virtually unchanged over 3 months' follow-up without treatment.sf
Intravenous administration may not be the most practical preparation. The recent development
of an oral preparation may be more suitable in patients with LC, The experience with orally
active prostaglandins in claudication is more limited, with only two published reports for evalua-
tion. Beraprost is a PGI2 analog that is orally active. A single phase II dose-ranging study has
been published in which 164 patients were randomized to placebo or three doses of drug.40
The improvement in absolute claudication distance over placebo was as follows: 60 /lg/d pro-
duced a 48% increase, 120 /lg/d a 51% increase, and 180 /lg/d a 31% increase (Table 16).
None of these changes was statistically significant. A concern was that at the highest dose, 62%
of the patients reported side effects of headache, flushing, and gastrointestinal intolerance.
Several phase III trials are evaluating the effectiveness of these drugs in claudication, and it is
hoped that these studies will clarify the utility of this class of drug.
Critical Issue 8: Use of prostanoids for symptoms of intermittent claudication
There is a need to investigate the possibly greater efficacy of prostanoids in patients
with intermittent claudication, because most randomized, open, or double-blind trials
with intraarterial or intravenous prostanoids have been performed in patients with end-
stage critical limb ischemia. Predictors to select the most suitable patients for prostanoid
treatment need to be determined.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are mito-
genic agents for the development of new collateral channels in models ofperipheral ischemia.
VEGF has been shown to augment collateral vessel development and increase capillary density
in skeletal muscle in a rabbit model.t! This effect has been observed when the VEGF protein is
administered by intraarterial infusion and when the DNA encoding for VEGF is given by intra-
muscular illjection.42 Early phase I and phase II trials are now in progress to determine whether
this novel therapy has a clinical application in patients with claudication and severe leg ischemia.
JOU~"AL OF VASCULAR SURGERY
Volume 3\, Number l , Part 2 B4 Treatment of Intermittent Claudication 595
Other new agents
L-arginine is an amino acid that has been shown to improve nitric oxide formation and
endothelial-dependent vasodilatation in patients with atherosclerosis. A few small studies have
been performed with this compound in patients with claudication.43,44 These studies have
shown improvements in pain-free and maximal walking distance, but larger studies are necessary
to determine the benefit of this treatment. Another new classof agent is drugs that open potas-
sium channels in vascular smooth muscle. In animal studies, this unique vasodilating drug
improves muscle blood flow and energy metabolism in experimental models of vascular dis-
ease.45 Other metabolic factors that may be addressed in PAD include modification of the bal-
ance between fatty acids versus carbohydrates as substrates for ischemic skeletal muscle.
Although fatty acids are a plentiful source of energy, they require relatively more oxygen than
carbohydrates for complete oxidation. The adenosine triphosphate (ATP)/oxygen ratio is 5.7
for fatty acids and 6.3 for glucose. Thus, when oxygen is limited, as during claudication, a shift
toward carbohydrate metabolism would be favorable in terms of ATP production. Several agents
are now under investigation that address these concepts.
B 4.2.5 Summary: Pharmacotherapy for Symptoms of Intermittent Claudication
In summary, patients with I'C have cardiovascular risk factors that are critical to identify and
modify to decrease the mortality risk of coronary and cerebrovascular disease. The pharmaco-
logical treatment of claudication itself is limited to a few drugs of uncertain efficacy. However,
several new drugs are under investigation and may show marked benefit in the direct treatment
of claudication symptoms.
Critical Issue 9: New pharmacological agents for symptoms of intermittent claudication
There is a need for extensive clinical trials to identify the place, if any, of emerging phar-
macological agents in the treatment of symptoms of intermittent claudication. Such
pharmacological agents may fill the need for an additional effective therapy besides exer-
cise training and intervention.
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